At the prospect of refinancing during the spring, Biosensor has been carrying on discussions with financial as well as industrial parties. The Company came to the conclusion that significant information about the Company could reach parties other than those with whom discussions were conducted. As a security measure, and to avoid abnormal stock price volatility, the Company, in consultation with AktieTorget, chose to suspend trading in the Biosensor share until further notice.
Facing the aforementioned refinancing, the Company can now announce that an agreement has been reached with financiers and principal owners for a bridge financing making MSEK 8 available to the Company to secure its financing until the above mentioned round of financing.
The Board of Directors has decided to reschedule the planned rights issue to take place during the second quarter.
For additional information, please contact:
Erik Lissner
President, Biosensor Applications Sweden AB (publ)
Telephone: + 46 8 706 75 00
E-mail: email hidden; JavaScript is required
Biosensor is a Swedish company listed on AktieTorget. The head office is located in Solna, a suburb of Stockholm. The Company has developed a method for detection of narcotics and explosives. This technology is based on super-sensitive biotechnological sensors that are able to detect and analyse these substances simultaneously, even at a molecular level. The technology is accurate, with low false alarm rates, even outside laboratory environments. Biosensor’s customers are found among police forces, security companies, border control, the armed forces, the criminal justice system and rehabilitation clinics on a world-wide basis.